Roland Grandel

This inventor holds 23 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Abbott Gmbh & Co Kg, Abbvie Deutschland Gmbh and Co Kg, Basf Aktiengesellschaft. Active years: 2002-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roland Grandel. Retrieved from https://idiyas.com/inventor/roland-grandel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 1)

% Patents Active = 34.8

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 6.8

ph-index = 7

Forward Citations = 135(Granted Patents)

Location History:

Bad Rappenau, DE (2013)
Dossenheim, DE (2002 - 2015)

Company Filing History:

Abbvie Deutschland Gmbh and Co Kg

patents

2 out of 10,816

Basf Aktiengesellschaft

patents

4. 1 out of 4,187

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2002-2015

Loading Chart...

Areas of Expertise:

Dopamine D3 Receptor

Serotonin 5HT6 Receptor

PARP Inhibitors

Heterocyclic Compounds

Aromatic Compounds

Aminoehtylaromatic Compounds

Arylsulfonamide Compounds

Benzimidazoles

Triazole Compounds

Dibenzodiazepine Derivatives

Azabicycloheptyl Compounds

Heterocyclic Aryl Sulphones

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8969552 - Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor (2015-03-03),

2. 8642642 - Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor (2014-02-04),

3. 8497273 - Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor (2013-07-30),

4. 8486984 - [object Object] (2013-07-16),

5. 8476275 - N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor (2013-07-02),

6. 8470810 - Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor (2013-06-25),

7. 8383641 - Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor (2013-02-26),

8. 8232426 - Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor (2012-07-31),

9. 8207160 - [object Object] (2012-06-26),

10. 8202868 - [object Object] (2012-06-19),

11. 7994160 - Pyridazine compounds as glycogen synthase kinase 3 inhibitors (2011-08-09),

12. 7851463 - [object Object] (2010-12-14),

13. 7834048 - Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor (2010-11-16),

14. 7759397 - [object Object] (2010-07-20),

15. 7320979 - N-[(piperazinyl)hetaryl]arylsulfonamide compounds (2008-01-22),

Title: Roland Grandel - Pioneer in Pharmaceutical Innovations

Introduction: Roland Grandel, a distinguished inventor in the field of pharmaceuticals, hails from Dossenheim, Germany. With a remarkable portfolio of 23 patents to his name, he has made significant contributions to the development of novel compounds for treating various medical disorders.

Latest Patents: Among his latest patents are groundbreaking discoveries in the realm of medicinal chemistry. One of his inventions involves arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds designed for disorders responsive to dopamine D3 receptor modulation. Another significant patent pertains to heterocyclic arylsulphones tailored for disorders sensitive to serotonin 5HT6 receptor modulation.

Career Highlights: Roland Grandel has garnered experience and expertise through his tenure at renowned companies such as Abbott GmbH & Co. KG and BASF Aktiengesellschaft. His innovative spirit and dedication to pharmaceutical research have shaped his career into one marked by numerous achievements and advancements in drug discovery.

Collaborations: Throughout his professional journey, Roland Grandel has collaborated with esteemed colleagues like Wilfried Martin Braje and Karla Drescher. These collaborations have fostered a culture of innovation, knowledge-sharing, and collective success in the field of pharmaceutical research.

Conclusion: In conclusion, Roland Grandel stands out as a pioneering inventor whose inventive solutions have the potential to revolutionize the pharmaceutical landscape. His inventive prowess, coupled with his collaborative spirit, continues to drive advancements in the development of novel therapeutic compounds.

Profile summary based on public USPTO records.